Humana Acquires Anvita Health, a Leading Health Care Analytics Company

Acquisition will strengthen Humana’s ability to help health plan members live healthier lives

LOUISVILLE, Ky.--()--Humana Inc. (NYSE: HUM) announced today it has acquired Anvita HealthTM, a San Diego-based health care analytics company. Terms were not disclosed.

Anvita Health, founded in 2000, provides analytics solutions that produce clinical insights for companies that want to improve the quality and lower the cost of health care for their members and clients. The Anvita Insight engine analyzes health data from more sources than any other analysis engine, and is highly scalable.

“We’ve been partnering with Anvita since 2010 to enhance Humana’s health care analytics performance, and we’re excited about what this acquisition will mean for Humana health plan members, health care providers and employer-customers,” said Michael B. McCallister, Humana’s Chairman and Chief Executive Officer. “Anvita helps its clients improve health care quality while also identifying cost savings for individuals and populations.”

Humana already uses Anvita’s innovative and pioneering Anvita Insight engine to identify members’ gaps in care and drug-safety concerns. Based on insights generated by Anvita, Humana initiates automated messaging to members, health care providers and its own service associates to help ensure that members and their care providers are getting information they need when they need it.

“Anvita’s purpose is to transform enormous volumes of clinical data into actionable intelligence for the benefit of all of Humana’s constituencies, as well as across the health care system,” said Ahmed Ghouri, M.D., Co-Founder and Chief Medical Officer of Anvita Health. “Humana is concerned not only with helping its own members and customers but also with helping the overall health system work better for everyone’s benefit. We can help them do that.”

“As Humana seeks to optimize the ways the company touches all levels of the health care system, it’s increasingly necessary to implement an even broader set of clinical outreach efforts and to deploy stronger analytical tools,” said Paul Kusserow, Humana’s Chief Strategy and Corporate Development Officer. “Anvita will help Humana strengthen its clinical management across a broad array of company initiatives.”

Anvita Health will continue to operate independently as a subsidiary of Humana, serving customers at all points in the health care ecosystem. Humana’s acquisition of Anvita is not expected to have a material impact on Humana’s financial earnings guidance for either of the years ending December 31, 2011 or December 31, 2012.

About Anvita Health

Founded by physicians in 2000, Anvita Health (formerly SafeMed) provides innovative clinical analytics to its customers who, combined, manage more than 100 million lives in the U.S. Anvita Health provides high-performance clinical analytics solutions for health plans, pharmacy benefit managers, personal health record and electronic health record companies, and health care providers. Anvita Health is headquartered in San Diego, California.

For more information about Anvita Health, visit www.anvitahealth.com.

Cautionary Statement

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

  • Health insurance reform legislation, including The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010, could have a material adverse effect on Humana’s results of operations, including restricting revenue, enrollment and premium growth in certain products and market segments, increasing the company's medical and administrative costs by, among other things, requiring a minimum benefit ratio, lowering the company’s Medicare payment rates and increasing the company’s expenses associated with a non-deductible federal premium tax; financial position, including the company's ability to maintain the value of its goodwill; and cash flows. In addition, if the new non-deductible federal premium tax is imposed as enacted, and if Humana is unable to adjust its business model to address this new tax, there can be no assurance that the non-deductible federal premium tax would not have a material adverse effect on the company’s results of operations, financial position, and cash flows.
  • If Humana does not design and price its products properly and competitively, if the premiums Humana charges are insufficient to cover the cost of health care services delivered to its members, or if its estimates of benefit expenses are inadequate, Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. These estimates, however, involve extensive judgment, and have considerable inherent variability that is extremely sensitive to payment patterns and medical cost trends.
  • If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, the company’s business may be materially adversely affected, which is of particular importance given the concentration of the company’s revenues in the Medicare business.
  • If Humana fails to properly maintain the integrity of its data, to strategically implement new information systems, or to protect Humana’s proprietary rights to its systems, the company’s business may be materially adversely affected.
  • Humana is involved in various legal actions and governmental and internal investigations, including without limitation, an ongoing internal investigation related to certain aspects of its Florida subsidiary operations, the outcome of any of which could result in substantial monetary damages, penalties, fines or other sanctions. Increased litigation or regulatory action and any related negative publicity could increase the company’s cost of doing business.
  • Humana’s business activities are subject to substantial government regulation and related audits for compliance, including, among others, existing audits regarding Medicare risk adjustment data. New laws or regulations, or changes in existing laws or regulations or their manner of application, including the methodology that may be used by the government in implementing results of risk adjustment audits, could increase the company’s cost of doing business and may adversely affect the company’s business, profitability and financial condition. In addition, as a government contractor, Humana is exposed to additional risks that may adversely affect the company’s business or the company’s willingness to participate in government health care programs.
  • On February 25, 2011, the Department of Defense TRICARE Management Activity, or TMA, awarded the TRICARE South Region contract to Humana. On March 7, 2011, the competing bidder filed a protest of the award with the Government Accountability Office. Also on March 7, 2011, as provided in the Federal Acquisition Regulations, TMA issued a stop work order to Humana in connection with the award. On June 14, 2011, the GAO upheld the award of the contract to Humana and TMA subsequently lifted the stop work order. On June 21, 2011, the competing bidder filed a complaint in the United States Court of Federal Claims objecting to the award of the contract to Humana. On October 14, 2011, the Court upheld the award of the contract to Humana, and the competing bidder has until December 13, 2011, to appeal it in the Court of Appeals for the Federal Circuit. As a result of the award of the TRICARE South Region contract to the company, Humana no longer expects a goodwill impairment to occur during the second half of 2011. Ultimate disposition of the contract award is, however, subject to the resolution of any additional actions the unsuccessful bidder may take.
  • Any failure to manage administrative costs could hamper Humana’s profitability.
  • Any failure by Humana to manage acquisitions and other significant transactions successfully may have a material adverse effect on its results of operations, financial position, and cash flows.
  • If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.
  • Humana’s home-delivery pharmacy business is highly competitive and subjects it to regulations in addition to those the company faces with its core health benefits businesses.
  • Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.
  • If Humana does not continue to earn and retain purchase discounts and volume rebates from pharmaceutical manufacturers at current levels, Humana’s gross margins may decline.
  • Humana’s ability to obtain funds from its subsidiaries is restricted by state insurance regulations.
  • Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.
  • Federal government contracts account for a substantial portion of Humana’s revenue and earnings. A delay by Congress in raising the federal government’s debt ceiling, should it occur, could lead to a reduction, suspension or cancellation of federal government spending that could, in turn, have a material adverse effect on Humana’s business and profitability.
  • Changes in economic conditions could adversely affect Humana’s business and results of operations.
  • The securities and credit markets may experience volatility and disruption, which may adversely affect Humana’s business.
  • Given the current economic climate, Humana’s stock and the stock of other companies in the insurance industry may be increasingly subject to stock price and trading volume volatility.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

  • Form 10-K for the year ended December 31, 2010;
  • Form 10-Q for the quarters ended March 31, 2011, June 30, 2011, and September 30, 2011;
  • Form 8-Ks filed during 2011.

About Humana

Humana Inc., headquartered in Louisville, Kentucky, is a leading health care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses, Humana believes it can better explore opportunities for existing and emerging adjacencies in health care that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases
  • Replays of most recent earnings release conference calls
  • Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
  • Corporate Governance information

Contacts

Humana Investor Relations
Regina Nethery, 502-580-3644
rnethery@humana.com
or
Humana Corporate Communications
Tom Noland, 502-580-3674
tnoland@humana.com
or
Anvita Health
Gretchen Griswold, 858-554-1886 ext. 325
ggriswold@anvitahealth.com

Sharing

Contacts

Humana Investor Relations
Regina Nethery, 502-580-3644
rnethery@humana.com
or
Humana Corporate Communications
Tom Noland, 502-580-3674
tnoland@humana.com
or
Anvita Health
Gretchen Griswold, 858-554-1886 ext. 325
ggriswold@anvitahealth.com